GSK971086

GSK971086 is an investigational small molecule drug developed by GlaxoSmithKline (now GSK) as a selective androgen receptor modulator (SARM). It was designed to target androgen receptors in specific tissues, aiming to provide anabolic benefits for muscle wasting conditions such as sarcopenia and androgen deficiency while minimizing unwanted androgenic side effects. The compound underwent early-stage clinical trials, including Phase 1 studies in healthy adult male volunteers, to assess its safety, tolerability, and pharmacokinetics. No further development has been reported since the completion of these initial studies[1][2][4][5].

Other names

1018971-95-38TFL50092H